Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 3Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 12INDUSTRY 2NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasm Metastasis 1

Interventions

Specimen Handling 188Magnetic Resonance Spectroscopy 143Biopsy 116Nivolumab 39X-Rays 29Immunoglobulin G 29Disulfides 29Radiation 28Carboplatin 27atezolizumab 25Taxes 25Paclitaxel 25pembrolizumab 23Radiotherapy 23Ipilimumab 23CTLA-4 Antigen 23olaparib 22Cyclophosphamide 22Cisplatin 21Platinum 20Gemcitabine 20Doxorubicin 20Bevacizumab 201,2-diaminocyclohexaneplatinum II citrate 20Phantoms, Imaging 19Vincristine 17trametinib 16cabozantinib 15Rituximab 15ibrutinib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × NIH × Panitumumab × Clear all
NCT05638295 2026-05-13

Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
105 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡